What this Trial Is About

This research focuses on patients diagnosed with chronic hepatitis B (CHB). It aims to study the molecular characteristics of hepatitis B virus (HBV), including genotypes, viral integration, drug resistance, and mutations, and how these relate to clinical immune phases and various clinical outcomes. The study includes two patient groups based on their cohort sources: those receiving antiviral treatment and those participating in a cross-sectional epidemiological survey, some of whom do not receive antiviral therapy. Patients in the Antiviral Treatment Cohort have been treated and are monitored every six months to track HBV-related events such as cirrhosis complications, hepatocellular carcinoma, liver transplantation, and liver-related death. The Cross-Sectional Epidemiological Survey Cohort involves one-time clinical data collection. Both groups provide retained blood and liver tissue samples used for analyzing HBV genetic features. The study investigates how these viral molecular characteristics connect with demographics, clinical phases, and health outcomes. Participants will provide clinical data and biological samples for analysis. Researchers will examine changes in HBV integration sites and counts using previously collected samples from 2015 to 2023. Detailed clinical information, genetic mutation profiles, and drug resistance patterns will be assessed alongside patient follow-up data to understand disease progression and treatment effects. The study involves long-term monitoring for those under antiviral treatment and single-point assessment for others, with comprehensive data collection to correlate molecular findings with patient health status.

Molecular Characteristics of Hepatitis B Virus Integration, Mutation, and Drug Resistance